The antiviral drug tenofovir alafenamide (TAF) has been used since 2015 in different combinations for the treatment of HIV and has already been subject to 3 early benefit assessments for this therapeutic indication. It has ...
0
0
Researchers at pharmaceutical giant Eli Lilly have developed a continuous manufacturing process for a chemotherapy drug, officials with the company recently announced. In their paper published in the journal Science, the ...
The vaccines unit of French pharmaceutical company Sanofi SA will pay a $19.9 million fine for overcharging the U.S. Department of Veterans Affairs for two products between 2002 and 2011.
0
0
Since August 2016 crizotinib (trade name: Xalkori) has also been available for adults with advanced non-small cell lung cancer (NSCLC) in whom the structure of the enzyme "proto-oncogene tyrosine-protein kinase" (ROS1) is ...
0
0
Crizotinib (trade name: Xalkori) has been available since 2012 for patients with advanced non-small cell lung cancer (bronchial carcinoma) with high activity of the enzyme anaplastic lymphoma kinase (ALK) who have already ...
1
0
Nivolumab (trade name: Opdivo) has been approved since June 2015 for adults with advanced melanoma. The German Institute for Quality and Efficiency in Health Care (IQWiG) had examined its added benefit in a dossier assessment ...
0
0
Anti-addiction activists are calling on a Senate committee to release findings from a 3-year-old investigation into links between painkiller manufacturers and nonprofit medical groups.
9
0
All was quiet Wednesday at a GlaxoSmithKline pharmaceutical plant that was shut down after the drug maker discovered the bacteria that cause potentially fatal Legionnaires' disease in a cooling tower at the site.
10
0
Drugmaker GlaxoSmithKline shut down a plant Tuesday that produces inhaled medications after discovering the bacteria that causes Legionnaire's disease, a potentially fatal form of pneumonia.
6
0
The National Institute for Health and Care Excellence (NICE) says it cannot give a positive decision over whether to recommend a new drug for ovarian cancer unless its makers provide more information on cost. A final decision ...
10
0
Subscribe to rss feed
